As shown in Fig. 7L, the immunoblot assay indicated that ccRCC cells treated with gefitinib showed an inhibition of the EGFR/AKT signaling axis induced by PLOD2. Here, PLOD2 is linked to nonpapillary renal cell carcinoma.